Table 4.

Test of significance in relapse rates among different groups

Groups comparedχ2 or cvalueaP valueTable no.
Primaquine vs bulaquine (1-yr follow-up)χ2 = 0.44 (df = 1)0.7 > P > 0.51
Combined treatment vs placebo (1-yr follow-up)χ2 = 9.66 (df = 1)0.01 > P > 0.0011
Short term in primaquine vs bulaquine (within 6 mo)χ2 = 0.05 (df = 1)0.9 > P > 0.82
Long term in primaquine vs bulaquine (within 7–12 mo)χ2 = 1.39 (df = 1)0.3 > P > 0.22
Short term in combined vs placebo (within 6 mo)χ2 = 0.83 (df = 1)0.4 > P > 0.32
Long term in combined vs placebo (within 7–12 mo)χ2 = 9.49 (df = 1)0.01 > P > 0.0012
Short and long in placebo, first half yr vs second half yrχ2 = 15.40 (df = 2) P < 0.0013
Short and long in bulaquine vs primaquine, first half yrχ2 = 4.82 (df = 2)0.1 > P > 0.053
Short and long in bulaquine vs primaquine, second half yrχ2 = 0.83 (df = 2)0.7 > P > 0.63
Short and long in combined vs placebo, first half yrχ2 = 0.40 (df = 2)0.9 > P > 0.83
Short and long in combined vs placebo, second half yrχ2 = 12.02 (df = 2)0.01 > P > 0.0013
Short term in combined vs placebo, first half yr c = 0.570.60 > P > 0.503
Short term in combined vs placebo, second half yr c = 0.660.50 > P > 0.403
Short term in combined, first half yr vs second half yr c = 2.94 0.01 > P > 0.0013
Long term in combined vs placebo, first half yr c = 0.170.9 > P > 0.83
Long term in combined vs placebo, second half yr c = 3.02 0.01 > P > 0.0013
Long term in combined, first half yr vs second half yr c = 4.11 P < 0.0013
  • a ∗, significant; df, degrees of freedom.